Marie De Santis

̵ Execution of the company’s strategy to develop and grow the Digital Health Division through pharma collaborations: contribution to the quantitative sales booking objective of the division by identifying, developing and closing deals with customers in the field ̵ Coordination of Business Development efforts in oncology, as a Therapeutic Area Lead: identification of priorities for the year, elaboration of strategy with management, development of specific campaigns to key stakeholders ̵ Transversal management of team (medical affairs, innovation, quality and regulatory, etc.) for multiple projects, both internal and external (ex: request for proposal to pharma) ̵ Participation to major global conferences in the field of oncology (ASCO, ESMO) and digital health (HLTH, Frontiers, Reuters) to ensure visibility of the division and foster customer intimacy with main stakeholders

̵ Contribution to successful transition efforts after Aptar-Voluntis acquisition in 2021, with adaptability and flexibility skills in a multicultural setting ̵ Formalization of new Aptar Digital Health offer to pharma with transversal efforts (generation of evidence with medical affairs team, identification of dataflow and interoperability with technical team, etc.) ̵ Visibility of the new Aptar Digital Health division with presence in the US and participation to major conferences in the field of oncology (ASCO in Chicago) and digital health (HLTH US, Bio ) to initiate and foster pharma relationship ̵ Preparation and presentation of onsite negotiation session with a pharma partner in New York (building of the contract with legal team, interaction with Business Development counterparts in pharma, negotiation strategy preparation with Chief Business Officer, execution with client and consultant onsite)

-Develop a thorough network and interact with pharma prospects to build and strengthen customer relationships in oncology and other therapeutic areas to establish new partnerships and reinforce Voluntis global footprint ̵Identify new commercial opportunities that are in line with the strategic objectives of the company including participation to relevant medical and business congresses and events ̵Analyze thoroughly both medical and business case for the use of digital therapeutics in oncology and other therapeutic areas for our customers ̵Coordinate the writing of commercial proposal with relevant departments (Medical, QA, Engineering, …) ̵Support KAM and VP Global Business Development in their activities and in reporting (CRM, contract management,…) ̵Contribute to continuous presence and visibility of Voluntis in the market by elaborating pertinent communication materials to sharpen the strategic positioning of Voluntis and ensure long term value creation in future partnerships with the help on the marketing team

̵ Scientific training of new hires (MSLs, commercial and medical affairs colleagues, post-doctoral fellows, etc.) on the product’s safety and clinical programs resulting in strong clinical acumen facilitating interactions with HCPs ̵ Medical oversight of planning and tactical milestones related to advisory boards (Treatment paradigm, MoA, Comparative treatment landscape) resulting in key information gathering facilitating strategy development and implementation ̵ Clinical support of regional subsidiaries (Europe, Emerging Markets, Asia-Pacific, Americas) for medical and commercial challenges resulting in significant regulatory and reimbursement outcomes ̵ Technical communication platform development supporting global and regional symposias and congresses focused on HCPs and payers

̵ Strategic planning and tactical execution resulting in successful launch of Ocrevus® in France ̵ Led development of disease state, product and comparator-focused communications for HCPs implemented through commercial field organization ̵ In charge of development and successful implementation of a patient journey project held on a national level with more than 50 hospital centers involved

̵ Development of scientific and commercial content and press releases supporting oncology products (Jakavi®, Tasigna®, Zykadia®) ̵ Implementation of institutional communication tools in the context of the Novartis-GSK oncology merger ̵ Planning and facilitation of commercial events supporting internal and external audiences: organization of the Cancer@Work regional meetings and planning of the world melanoma awareness day

̵ In charge of quality control of radioactive products Settings of a new protocol measuring the glomerular filtration rate in patients receiving radiotherapy interventions (this work was developed in a poster and presented in an academic clinical setting)

̵ Delivered disease management education and support ̵ Certification and delivery of prescriptions ̵ Checking of stocks and purchases ̵ Provided medication counseling

Vascular physiopathology research – work on the CD56

Thesis 2017: « Innovation in the therapeutic management of multiple sclerosis: what are the financing perspectives in France? »